Related Experiment Video
Updated: Jan 17, 2026

10:56
Endothelial Cell Transcytosis Assay as an In Vitro Model to Evaluate Inner Blood-Retinal Barrier Permeability
Published on: June 7, 2022
5.9K
Erucamide regulates retinal neurovascular crosstalk
Biorxiv : the Preprint Server for Biology
|September 15, 2025
Summary
Erucamide, a fatty acid amide, is diminished in retinal degeneration. Restoring erucamide levels activates myeloid cells, promoting factors that stabilize vision loss and offering a new therapeutic avenue.
Area of Science:
- Neuroscience
- Ophthalmology
- Biochemistry
Background:
- Neurovasculoglial crosstalk is essential for the neurovascular unit, and its breakdown contributes to central nervous system (CNS) neurodegenerative disorders, including retinal degeneration.
- Primary fatty acid amides (PFAMs) are implicated in regulating crosstalk between vasculature and neuronal tissues.
- Retinal degeneration involves complex cellular interactions and metabolic changes.
Purpose of the Study:
- To investigate the role of PFAMs, specifically erucamide, in retinal degeneration.
- To explore the therapeutic potential of erucamide delivery for stabilizing retinal degeneration.
- To identify the molecular targets and pathways involved in erucamide's action.
Main Methods:
- Global mass spectrometry-based metabolomics in murine models of retinal degeneration.
- In vivo delivery of erucamide using organosilane-modified porous silicon nanoparticles (pSiNPs) in rodent models.
- Analysis of myeloid cell activation, cytokine production, and identification of erucamide binding proteins.
Main Results:
- PFAMs are dysregulated in retinal degeneration, with erucamide being significantly diminished during photoreceptor atrophy.
- In vivo erucamide delivery via pSiNPs activated CD11b+ myeloid cells.
- Activated myeloid cells upregulated angiogenic and neurotrophic cytokines, stabilizing retinal degeneration.
- TMEM19 was identified as a novel erucamide binding protein crucial for macrophage precursor cell activation and factor production.
Conclusions:
- Erucamide plays a critical role in degenerating retinal tissues and its deficiency is linked to photoreceptor atrophy.
- Erucamide administration, facilitated by pSiNPs, demonstrates therapeutic potential by modulating myeloid cell responses.
- The erucamide-TMEM19 pathway represents a novel therapeutic target for retinal degenerative diseases, potentially offering an alternative to existing neuroprotective and stem cell therapies.
More Related Videos
09:10Direct-Coupled Electroretinogram DC-ERG for Recording the Light-Evoked Electrical Responses of the Mouse Retinal Pigment Epithelium
Published on: July 14, 2020
5.8K
09:33An Acute Retinal Model for Evaluating Blood Retinal Barrier Breach and Potential Drugs for Treatment
Published on: September 13, 2016
7.5K